Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

Discover BiomX's Q2 2025 updates, including progress in phage therapy trials BX004 & BX211, financial highlights, and key insights into upcoming ...

H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

People with multiple sclerosis tend to have frequent doctor's appointments up to 15 years before diagnosis, recent research ...

Cedars-Sinai physician-scientists joined peers from around the world at the Alzheimer's Association International Conference ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

Research and development spending rose 14.3% compared to Q2 2024, reflecting a busy clinical pipeline, while the net loss (GAAP) increased to $10.4 million. These 10 stocks could mint the next wave of ...

Private equity house LDC has backed the expansion plans of a North West-headquartered business which is the UK’s largest site ...

Key Points GAAP EPS loss of $9.09 was narrower than the expected $9.24 per share for Q2 2025, a minor outperformance. Research and development expenses (GAAP) rose 29.2% to $2.2 million, reflecting ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Phase 1 study results published in Nature Medicine looks at a vaccine for patients with pancreatic and colorectal cancer. Dr Magnus Dillon, Clinician Scientist at The Institute of Cancer Research, ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the results of ...